Aptinyx (NASDAQ:APTX) Upgraded by Zacks Investment Research to “Hold”
According to Zacks, “Aptinyx Inc. is a bio-pharmaceutical company. It focuses on discovery, development, and commercialization of novel, proprietary and synthetic small molecules for the treatment of brain and nervous system disorders. The company’s product pipeline consists of NYX-2925, NYX-783 and NYX-458 which are in clinical stage. Aptinyx Inc. is based in IL, United States. “
Several other equities research analysts have also issued reports on APTX. JPMorgan Chase & Co. lowered Aptinyx from a neutral rating to an underweight rating in a research note on Tuesday, August 13th. Cowen reaffirmed a buy rating on shares of Aptinyx in a research note on Thursday, November 14th. ValuEngine raised Aptinyx from a hold rating to a buy rating in a research note on Thursday, August 1st. BMO Capital Markets lowered their price objective on Aptinyx from $15.00 to $13.00 and set an outperform rating for the company in a research note on Wednesday, November 13th. Finally, Wedbush started coverage on Aptinyx in a research note on Thursday, September 12th. They issued an outperform rating and a $7.00 price objective for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $11.11.
Aptinyx (NASDAQ:APTX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.44) EPS for the quarter, meeting analysts’ consensus estimates of ($0.44). Aptinyx had a negative return on equity of 44.24% and a negative net margin of 1,523.09%. The company had revenue of $0.94 million during the quarter, compared to analyst estimates of $0.91 million. As a group, research analysts predict that Aptinyx will post -1.89 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of APTX. Vanguard Group Inc. increased its holdings in Aptinyx by 56.6% during the 2nd quarter. Vanguard Group Inc. now owns 728,689 shares of the company’s stock worth $2,434,000 after purchasing an additional 263,458 shares during the period. Russell Investments Group Ltd. purchased a new position in Aptinyx during the 3rd quarter worth $260,000. Jane Street Group LLC purchased a new position in Aptinyx during the 2nd quarter worth $222,000. Paloma Partners Management Co purchased a new position in Aptinyx during the 2nd quarter worth $207,000. Finally, Acadian Asset Management LLC purchased a new position in Aptinyx during the 2nd quarter worth $195,000. Hedge funds and other institutional investors own 52.14% of the company’s stock.
Aptinyx Company Profile
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.